-
-
-
-
-
-
-
Pfizer's (PFE) LORBRENA CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
-
-
-
-
-
-
-
AbbVie (ABBV) Receives Positive CHMP Opinion for Risankizumab
-
-
-
-
-
-
-
Summit Therapeutics (SMMT): Ivonescimab Beats Pembrolizumab Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous Levothyroxine (XP-8121)
-
-
-
-
-
-
-
Mira Pharma (MIRA) Announces DEA Ruled MIRA-55 Not Classified as a Controlled Substance
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Reports Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
-
-
-
-
-
-
-
TScan Therapeutics (TCRX) Receives FDA’s Regenerative Medicine Advanced Therapy Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
-
67,234 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.
